PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025.
About embecta
embecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Contacts:
| Media Christian Glazar Sr. Director, Corporate Communications 908-821-6922 Contact Media Relations | Investors Pravesh Khandelwal VP, Head of Investor Relations 551-264-6547 Contact IR |
| Last Trade: | US$12.57 |
| Daily Volume: | 0 |
| Market Cap: | US$735.220M |
November 25, 2025 November 17, 2025 August 08, 2025 February 06, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
